A Phase 1 Study of JNJ-89862175, an Antibody Drug Conjugate (ADC) Agent Targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 (ENPP3), for Advanced Solid Tumors
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Location
-
Principal Investigator
-
Sponsor
Janssen Research & Development LLC
A Phase 1 Study of JNJ-89862175, an Antibody Drug Conjugate (ADC) Agent Targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 (ENPP3), for Advanced Solid Tumors
Enrollment Form
This study is currently enrolling.